PLYMOUTH, Minn., July 28, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the Company will be participating in two upcoming investor conferences.
Entellus Medical's management is scheduled to present at the Wedbush PacGrow Healthcare Conference in New York City, NY on Tuesday, August 11 at 10:20am EDT.
Entellus Medical's management is also scheduled to present at the Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 12 at 11:00am EDT.
Interested parties can access the live audio webcast for both of these presentations at http://www.entellusmedical.com. An archived presentation will be available on the website for 30 days.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS. Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the UK.